Topic:

Venture Capital

Latest Headlines

Latest Headlines

Dermira pockets $51M to bankroll skin treatments

Well-funded biotech Dermira has landed a $51 million C round to support its late-stage dermatology pipeline, rallying some high-profile investors as it dials up R&D spending and builds out its management team.

Tolero bags $14M to take its cancer drug to Phase III

Salt Lake City biotech Tolero Pharmaceuticals has raised $14.2 million in Series B cash to bankroll the development of alvocidib, a marrow cancer treatment on the verge of late-stage trials.

Juno stuffs its CAR-T war chest with another $134M fundraise

Superlatively well-funded biotech startup Juno Therapeutics has bagged another $134 million in venture cash, bringing its 12-month total north of $300 million as it races to advance a new therapeutic approach that could transform cancer treatment.

Fecal-transplant specialist Rebiotix nabs $25M round

Roseville, MN-based Rebiotix says it raised $25 million in a Series B, designed to fund pivotal work on its lead fecal-transplant program for RBX2660.

Bristol-Myers is seeding a new crop of biotech spinouts, buyout options included

Bristol-Myers Squibb has formed a new joint venture with Boston-based Allied Minds that will hunt the groves of academia in an enterprising approach to launching new biotechs and bagging new drug candidates.

Venrock unveils a $450M new fund with eyes on biotech

Well-heeled venture capital firm Venrock has pieced together a 7th fund, banking $450 million in new investments as it sets out to grow its portfolio of promising startups.

Cold Genesys rakes in $13.6M for its cancer-fighting virus

California biotech Cold Genesys has wrapped up a $13.6 million A round to support its work on cancer treatment that promises to infect tumor cells and convince the immune system to join the fight.

Big Pharma is using its venture cash to outsource early R&D to biotech

Analysts at Silicon Valley Bank have been crunching the numbers on biotech investing, and they have found that a group of busy corporate venture arms has fundamentally changed the landscape for startups and the entire field of early-state drug development--with some big implications for the current crop of industry upstarts.

Ex-Pfizer exec Schulman lands at Polaris after an abrupt departure

Months after a swift exit from Pfizer's highest ranks, Amy Schulman has made her next move, joining high-profile biotech investor Polaris as a venture partner

Pfizer, Lilly and J&J chip in on $51M seed fund for New York biotechs

Three Big Pharma companies have helped come up with some seed money to start growing the first crop of biotechs in New York. Pfizer, Eli Lilly and J&J all chipped in to a $51 million fund from Accelerator Corp., which will now expand on the work it's been doing in Seattle to the East Side of Manhattan, recruiting upstarts to join investigators at the Alexandria Center for Life Science.